Angioedema: Etiology, pathophysiology, current and emerging therapies

Lawrence M. Lewis

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Background Angioedema (AE) is characterized by nonpitting edema of the dermis and subcutaneous layers. The most common sites of involvement are the tongue, lips, face, and throat; however, swelling can also occur in the extremities, genitalia, and viscera. Life-threatening airway swelling can also occur. AE may be allergic or nonallergic. The overall lifetime incidence of AE is reported to be as high as 15%. Objective This article summarizes the etiology, pathophysiology, and current treatment of several forms of nonallergic AE (including hereditary, acquired, and idiopathic AE) and focuses on angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE), which is responsible for 30%-40% of all AE seen in United States emergency departments. Discussion Although the triggers, which are primary biologic mechanisms, and treatments for ACEi-AE may differ from those of the hereditary and acquired forms of AE, the clinical effects of ACEi-AE are mediated through a shared pathway, the kallikrein-kinin system. Thus, although current therapeutic options for ACEi-AE are limited, recent advances in the treatment of hereditary AE (HAE) appear promising for improving the outcomes of patients with ACEi-AE. Conclusions New HAE medications that correct imbalances in the kallikrein-kinin system may prove safe and efficacious in the treatment of ACEi-AE.

Original languageEnglish
Pages (from-to)789-796
Number of pages8
JournalJournal of Emergency Medicine
Issue number5
StatePublished - Nov 2013


  • angioedema
  • angiotensin-converting enzyme inhibitor-induced angioedema
  • ecallantide
  • icatibant
  • kallikrein-kinin system


Dive into the research topics of 'Angioedema: Etiology, pathophysiology, current and emerging therapies'. Together they form a unique fingerprint.

Cite this